(R)-6-(2,3-dihydroxypropyl)-4-(2-fluoro-4-iodophenylamino)-1-methyl-1,6-naphthyridine-2,5(1H,6H)-dione | 1189047-45-7

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: (R)-6-(2,3-dihydroxypropyl)-4-(2-fluoro-4-iodophenylamino)-1-methyl-1,6-naphthyridine-2,5(1H,6H)-dione
• 英文别名: 6-[(2R)-2,3-dihydroxypropyl]-4-(2-fluoro-4-iodoanilino)-1-methyl-1,6-naphthyridine-2,5-dione
• CAS: 1189047-45-7
• 化学式: C₁₈H₁₇FIN₃O₄
• 分子量: 485.254
• InChiKey: VSHLWYKGFQDDIZ-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  93.1
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• MAPK/ERK KINASE INHIBITORS AND METHODS OF USE THEREOF
  申请人：Dong Qing

  公开号：US20090246198A1

  公开（公告）日：2009-10-01

  Compounds of the following formula are provided: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  提供以下公式的化合物：其中变量的定义如本文所述。还提供包含这些化合物的药物组合物、试剂盒和制造品；用于制备这些化合物的方法和中间体；以及使用这些化合物的方法。
• METHOD OF REDUCING ADVERSE EFFECTS IN A CANCER PATIENT UNDREGOING TREATMENT WITH A MEK INHIBITOR
  申请人：THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV

  公开号：US20150265679A1

  公开（公告）日：2015-09-24

  What is described is a method for treating an adverse side effect of MEK inhibitors by administering a pharmaceutical composition comprising IFNγ to a cancer patient being treated by a MEK-inhibitor. The applicants discovered that MEK inhibitors produce unwanted visual disturbances as an adverse side effect in a significant fraction of cancer patients being treated by the drug, and that the side effect causes retinal detachment due to fluid accumulation in the eye. The method treats the retinal detachment caused by the anticancer therapeutic by providing a means of decreasing the amount of fluid present in the retina and/or subretinal space of the eye by administering the pharmaceutical composition comprising IFNγ to the basolateral side of the retinal pigment epithelium, preferably by administering the pharmaceutical composition to the anterior surface of the eye in liquid droplets.
• [EN] MAPK/ERK KINASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE KINASES MAPK/ERK ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2009146034A2

  公开（公告）日：2009-12-03

  Compounds of the following formula are provided: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.